About Survodutide

Survodutide is a new drug for the treatment of overweight or obesity.
Not yet approved or available.
An injection that acts on two of the body’s own hormones.
Possible average weight loss of up to 16.6% at the highest dosage.
The side effects are similar to those of other GLP-1 drugs.

What is Survodutide?

A novel drug called survodutide is being developed for individuals with fatty liver disease and those who are overweight or obese. In addition to a changed diet and more exercise, it is being evaluated as a weekly subcutaneous injection. Particularly, weight loss, enhanced liver function, and decreased liver inflammation are the main goals of the research. Two bodily signals that control hunger, fullness, and energy expenditure are impacted by the active component. This might aid in cutting back on food consumption. Currently undergoing clinical trials, survodutide is neither authorized nor accessible in the European Union. As soon as this changes, we’ll let you know.

Effect of Survodutide

GLP-1 and glucagon are two of the body’s natural signals that survodutide imitates. GLP-1 can lessen hunger and provide a quicker sense of fullness. In addition to raising energy expenditure, glucagon may have an impact on hepatic fat storage. The medication can act concurrently at several locations throughout the body thanks to this combination.

Side effects of Survodutide

The known side effects mainly affect the gastrointestinal tract:

nausea
Vomit
Diarrhea

These side effects are similar to those of weight-loss medications already on the market. They may lessen or disappear over time, depending on how frequently the medication is used.

Research on Survodutide

After 76 weeks, the maximum dose examined in a phase 3 research involving overweight or obese individuals led to an average weight loss of almost 16.6%.

There are currently more extensive Phase 3 trials on obesity in progress. To definitively ascertain efficacy, safety, and the ideal dosage, more study is required. As soon as fresh information becomes available, we will let you know.